Actively Recruiting
Study to Assess Safety and Effectiveness of Recombinant Von Willebrand Factor With or Without ADVATE in Treating Bleeding for Chinese Adults With Von Willebrand Disease
Led by Takeda · Updated on 2026-01-08
20
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and how well the drug VONVENDI works in adult Chinese participants who have Von Willebrand Disease VWD. The study focuses on participants with severe VWD and aims to see how VONVENDI controls bleeding, both with and without the use of another drug called ADVATE, especially during elective surgeries or dental procedures. This phase 3 study also examines how VONVENDI is processed in the body and how it affects the bodys response to bleeding. Participants will receive a single intravenous dose of VONVENDI at the start for pharmacokinetic assessment. During a 12-month period, any bleeding episodes needing treatment with von Willebrand factor VWF replacement will be managed using VONVENDI, with or without ADVATE. The initial dose of VONVENDI ranges from 40 to 80 international units per kilogram of body weight. Additional infusions may be given as necessary for managing bleeding related to surgeries or dental procedures. Participants will be involved in the study for about 14 months, including the treatment and follow-up periods. They will have regular visits to clinics or telephone follow-ups to monitor their health, treatment effects, and any side effects. Researchers will track various safety measures such as adverse events, allergic reactions, antibody development, laboratory test results, and vital signs over this time. The study also measures how much of each drug is used per bleeding episode and how quickly bleeding resolves.
CONDITIONS
Brief Title
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here